

Maria Gerosa

List of Publications by Citations

Source: <https://exaly.com/author-pdf/115575/maria-gerosa-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

2,320
citations

27
h-index

46
g-index

82
ext. papers

2,939
ext. citations

6.3
avg, IF

4.8
L-index

#	Paper	IF	Citations
76	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. <i>Blood</i> , 2018 , 132, 1365-1371	7.1	359
75	Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1970-7		112
74	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 609-15	2.4	97
73	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 727-35	7	79
72	Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?. <i>Autoimmunity</i> , 2005 , 38, 39-45	3	74
71	Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. <i>Arthritis Research and Therapy</i> , 2014 , 16, 209	5.7	73
70	Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. <i>Arthritis Research and Therapy</i> , 2014 , 16, R144	5.7	72
69	Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2196-204	9.5	68
68	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019 , 18, 93-106	13.6	63
67	Patients with antiphospholipid syndrome display endothelial perturbation. <i>Journal of Autoimmunity</i> , 2010 , 34, 105-10	15.5	59
66	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. <i>Immunologic Research</i> , 2017 , 65, 17-24	4.3	58
65	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. <i>Journal of Autoimmunity</i> , 2018 , 86, 1-8	15.5	57
64	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. <i>Blood</i> , 2016 , 127, 365-7	2.2	51
63	P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2019 , 216, 317-336	16.6	49
62	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 639-646	7.6	48
61	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <i>Journal of Autoimmunity</i> , 2018 , 90, 1-27	15.5	46
60	Beyond thrombosis: Anti- β GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018 , 90, 76-83	15.5	41

59	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019 , 18, 406-414	13.6	39
58	New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. <i>Current Rheumatology Reports</i> , 2014 , 16, 402	4.9	39
57	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. <i>Journal of Rheumatology</i> , 2017 , 44, 1165-1172	4.1	35
56	Cardiac involvement in systemic autoimmune diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2002 , 23, 247-61	12.3	35
55	Endothelium as a target for antiphospholipid antibodies. <i>Immunobiology</i> , 2003 , 207, 29-36	3.4	34
54	Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. <i>Autoimmunity Reviews</i> , 2015 , 14, 686-91	13.6	33
53	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1150-1157	5.3	29
52	β ₂ Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. <i>Journal of Immunology</i> , 2017 , 198, 2640-2648	5.3	28
51	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018 , 9, 1388	8.4	28
50	Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?. <i>Rheumatology</i> , 2012 , 51, 2186-90	3.9	27
49	Updating on the pathogenic mechanisms of the antiphospholipid antibodies-associated pregnancy loss. <i>Clinical Reviews in Allergy and Immunology</i> , 2008 , 34, 332-7	12.3	27
48	Are patients with systemic lupus erythematosus at increased risk for COVID-19?. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e25	2.4	27
47	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019 , 18, 164-176	13.6	27
46	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , 2020 , 59, 1306-1314	3.9	26
45	The use of biologics and small molecules in pregnant patients with rheumatic diseases. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 987-998	3.8	25
44	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1314-1324	9.5	24
43	Challenges and treatment options for rheumatoid arthritis during pregnancy. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1539-47	4	24
42	Safety considerations when prescribing immunosuppression medication to pregnant women. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1591-9	4.1	23

41	Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 1505-17	5.1	23
40	Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block: lesson from twins and triplets discordant for the disease. <i>Arthritis and Rheumatism</i> , 2006 , 54, 356-9		23
39	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019 , 71, 134-141	4.7	23
38	Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. <i>American Journal of Reproductive Immunology</i> , 2015 , 73, 390-401	3.8	22
37	Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2016 , 7, 5	8.4	22
36	Recognition and management of antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 51-9	5.3	20
35	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021 , 60, 1114-1124	3.9	19
34	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. <i>Frontiers in Immunology</i> , 2019 , 10, 1948	8.4	17
33	"Disease knowledge index" and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019 , 86, 475-481	2.9	17
32	Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 688-93	2.2	17
31	Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 643-647	2.2	17
30	Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases). <i>Internal and Emergency Medicine</i> , 2008 , 3, 201-3	3.7	16
29	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report 2017 , 317-338		16
28	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019 , 10, 773	8.4	14
27	Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care and Research</i> , 2020 ,	4.7	13
26	Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin. <i>Obstetrics and Gynecology</i> , 2011 , 117, 177	4.9	12
25	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776	2.6	12
24	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 531-535	15.4	11

23	Lung Disease in Antiphospholipid Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019 , 40, 278-294	3.9	8
22	Circulating stem cell factor in patients with chronic idiopathic urticaria. <i>Annals of Allergy, Asthma and Immunology</i> , 2003 , 91, 79-81	3.2	8
21	Diversity and somatic hypermutation of the Ig VHDJH, V kappa J kappa, and V lambda J lambda gene segments in lymphoma B cells: relevance to the origin of the neoplastic B cell clone. <i>Human Immunology</i> , 2003 , 64, 69-81	2.3	7
20	Epigenetics, pregnancy and autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2020 , 19, 102685	13.6	7
19	Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis. <i>Swiss Medical Weekly</i> , 2016 , 146, w14394	3.1	6
18	Anti-phospholipid antibodies and reproductive failures. <i>American Journal of Reproductive Immunology</i> , 2021 , 85, e13258	3.8	6
17	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. <i>Biomedicines</i> , 2021 , 9,	4.8	4
16	Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. <i>Clinical Immunology</i> , 2021 , 231, 108845	9	3
15	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. <i>Journal of Autoimmunity</i> , 2021 , 124, 102729	15.5	3
14	Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. <i>Rheumatology</i> , 2021 ,	3.9	2
13	Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 841785	5.6	2
12	Autoantibodies [Future Trends 2014 , 825-828		1
11	Update on pregnancy in autoimmune diseases. <i>Womens Health</i> , 2007 , 3, 417-20	3	1
10	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 938-946	2.2	1
9	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2021 , 1	12.3	0
8	Pregnancy in juvenile idiopathic arthritis: maternal and foetal outcome, and impact on disease activity.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022 , 14, 1759720X221080375	3.8	0
7	Cardiovascular Issues in SLE. <i>Rare Diseases of the Immune System</i> , 2016 , 133-145	0.2	
6	Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2010 , 6, 18-24	1.6	

- 5 5th International Conference on Sex Hormones, Pregnancy and Rheumatic Disease. *Future Rheumatology*, **2007**, 2, 251-255
- 4 INTERFERON-INDUCIBLE PROTEIN IFI16 AUTOANTIBODIES **2007**, 331-337
- 3 Non-organ Specific Autoimmunity Involvement in Cardiovascular Disease. *Handbook of Systemic Autoimmune Diseases*, **2003**, 1, 41-51 0.3
- 2 Myocardial involvement in anti-phospholipid syndrome: Beyond acute myocardial infarction. *Autoimmunity Reviews*, **2021**, 102990 13.6
- 1 Ultrasound assessment of lacrimal glands: a cross-sectional study in healthy subjects and a preliminary study in primary Sjögren's syndrome patients. *Clinical and Experimental Rheumatology*, **2020**, 38 Suppl 126, 203-209 2.2